Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Acai, cacao and maca extracts: Anticancer activity and growth inhibition of microbial triggers of selected autoimmune inflammatory diseases

    wadmin2By wadmin2August 6, 2016Updated:August 11, 2021No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Xiaohong Wang1,2, Jiayu Zhang1,2, Ian Edwin Cock1,3*
    1School of Natural Sciences, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, AUSTRALIA.
    2School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, CHINA.
    3Environmental Futures Centre, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Brisbane, Queensland 4111, AUSTRALIA.

    Pharmacognosy Communications,2016,6,4,204-214.
    DOI:10.5530/pc.2016.4.3
    Published: August 2016
    Type: Original Article

    ABSTRACT

    Background: The consumption of high antioxidant foods has been linked with a decreased incidence of some cancers and inflammatory diseases. Some high antioxidant foods also inhibit the growth of a variety of bacterial pathogens. Despite this, the high antioxidant ‘superfoods’ acai, cacao and maca are yet to be adequately tested for anticancer activity or the ability to inhibit the growth of bacterial triggers of autoimmune inflammatory diseases. Materials and Methods: Freeze dried acai, cacao and maca powders were extracted and tested for antimicrobial activity using a modified disc diffusion assay and the MICs were determined. Inhibitory activity against CaCo2 and HeLa cancer cell lines was evaluated using colorimetric cell proliferation assays. Toxicity was evaluated using an Artemia franciscana nauplii bioassay. Results: The acai, cacao and maca extracts displayed broad spectrum antibacterial activity, inhibiting the growth of all of the bacteria screened, although generally with only low efficacy. The ethyl acetate extracts were more potent bacterial growth inhibitors than were the corresponding methanolic and aqueous extracts. The inhibitory activity of the acai and maca ethyl acetate extracts against P. mirabilis was particularly noteworthy, with MIC values <1000 μg/mL. The aqueous and methanolic extracts of all fruits had only low bacterial growth inhibitory activity. In contrast, the aqueous extracts of cacao and maca were the most effective at inhibiting proliferation of the colorectal cancer cell line CaCo2 (aqueous maca extract IC50=1800 μg/mL) and HeLa cervical cancer cell growth, (aqueous cacao extract IC50 values 1810 μg/mL). All extracts were non-toxic, with LC50 values substantially > 1000 μg/mL. Conclusion: These studies demonstrate that the aqueous cacao and maca extracts have appreciable inhibitory activity against some cancer cell lines and that the acai and maca ethyl acetate extracts were moderate inhibitors of the growth of bacteria associated with selected autoimmune inflammatory disorders. Furthermore, the toxicity studies indicate that they are safe for therapeutic usage. All other extracts were inactive or of low activity towards the cancer and bacterial cells.

    Key words: Euterpe oleracea, Lepidium meyenii, Theobroma cacao, Autoimmune inflammatory disease, Rheumatoid arthritis, Ankylosing spondylitis, Multiple sclerosis, Cancer.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up